Labquality is organising an EQA scheme for SARS-CoV-2 (COVID-19) detection.The new EQA combo scheme includes individual samples for both molecular diagnostics as well as for serological testing. The participants can choose to order both products or just one product type according to their needs.
REGISTRATION: Registration for pilot scheme has been closed due to unprecedented demand.
EQA Scheme information: LIMITED AVAILABILITY – Contact firstname.lastname@example.org immediately.
The SARS-CoV-2 EQA scheme is targeted to medical laboratories and POCT sites. Evaluation of the results is qualitative (pos/neg). There are two rounds available in 2020, to be sent out in September and November, which are chargeable.
Scheme 5676 SARS-CoV-2, nucleic acid detection: 2- 3 SARS-CoV-2 pos/neg samples will be included either as liquid samples or as swab samples. Each sample should be extracted by the recommended nucleic acid extraction method for the assay used by the participant. Samples contain a whole-genome product that includes all genetic sequences of the virus and emulate real patient samples. As such, the product used contains all possible NAT viral targets ensuring compatibility across all nucleic acid tests. The samples are non-infectious and stable. Cost is €484 for both distributions.
Scheme 5677 SARS-CoV-2, antibody detection: 2- 3 Anti-SARS-CoV-2 IgG/IgM pos/neg samples will be included (approx. 0.5mL/sample). Samples will be one-donor/pooled samples of human sera or plasma. Cost is €331 for both distributions.